VTRS · 10-Q · 2026Q2 · Full report

Product Launch and Transition

Viatris Inc · 2026-08-06 · Importance 46 · Surprise 42

Viatris’ constant-currency net sales increased 3% in the first six months of 2026, supported by approximately $171.8 million of new product sales, primarily in Developed Markets, and $60.7 million of net base business growth. Octreotide acetate in North America and estradiol transdermal systems were key growth products. In the second quarter, new product sales contributed approximately $101.0 million of growth, while the top ten products represented 39% of net sales versus 37% a year earlier. R&D investment increased for the selatogrel and cenerimod development programs, although the filing provides no clinical or regulatory milestone for either program.

Key facts

• The Company has approximately 1,300 approved molecules. source